Randox

What Randox does

Randox Laboratories Ltd is a privately held UK-based clinical diagnostics company headquartered in Crumlin, founded in 1982 by Peter FitzGerald. Operating in the in-vitro diagnostics market, Randox provides diagnostic testing solutions across clinical chemistry, immunochemistry, hematology, and veterinary diagnostics, and is the operator of the RIQAS external quality-assurance scheme that integrates into clinical laboratory workflows globally. The company has expanded into biochips for drug discovery and diagnostics through its acquisition of Cellix Limited, and extended its US manufacturing footprint via a Jefferson County facility expansion.

The company's commercial architecture combines multiple revenue-bearing activities: (1) diagnostic testing products and consumables supplied to clinical laboratories, (2) recurring revenue from the RIQAS quality-assurance program (recently deepened through the February 2025 partnership with Cormay Diagnostics), (3) consumer-facing services under the Randox Health brand, and (4) infrastructure-for-equity style partnerships with AI-driven health platforms such as Lucis. The company also operates the "Randox for Builders" incubator with MD One Ventures, targeting national-resilience and biotech startups, and has made early-stage investments in Untap Health and Airfinity (Dec 2025).

Randox's go-to-market is horizontal, serving clinical laboratories, healthcare companies, and preventive-health platforms across multiple geographies including the UK, the US (manufacturing in Jefferson County), and India (distribution in Bengaluru). Pricing is not publicly disclosed and the company is privately held with 1,001-5,000 employees, suggesting a mid-to-large privately held diagnostics operator. Randox does not develop proprietary AI/ML capabilities in-house; its AI exposure is indirect, as partners such as Lucis apply AI on top of biomarker data generated through Randox's diagnostic infrastructure.

Name

Randox

Legal name

Randox Laboratories Ltd

Website

https://randox.com

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Randox Laboratories Ltd is a UK-based, privately held clinical diagnostics company founded in 1982 that provides in-vitro diagnostic testing, external quality-assurance programs (RIQAS), and biochips solutions to clinical laboratories, veterinary diagnostics customers, and consumer health platforms globally.

Ownership category

akta.pro rank

Product category

Clinical Diagnostics / In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734), Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Clinical diagnostics
• In vitro diagnostics
• External quality assessment
• Diagnostic biochips
• Clinical chemistry reagents

Headquarters

HQ city

Crumlin

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales

Core offering

Randox develops, manufactures, and distributes in vitro clinical diagnostic products including reagents, analyzers, and proprietary biochip technology (via subsidiary Cellix Limited) for clinical laboratories and healthcare providers. The company also operates the RIQAS external quality assessment program covering hematology, clinical chemistry, and immunochemistry testing portfolios.

Differentiator

Problem solved

Functional benefit

Products and services

• RIQAS External Quality Assessment Scheme An external quality assessment (EQA) program operated by Randox that integrates multiple assay portfolios across hematology, clinical chemistry, and immunochemistry testing areas, used by clinical laboratories to benchmark and validate their diagnostic testing performance. The program has been expanded via integration partnerships such as Cormay Diagnostics (announced February 2025).
• Clinical Chemistry Diagnostic Reagents & Testing Solutions In vitro diagnostic reagents and testing solutions for clinical chemistry applications, distributed to clinical laboratories and integrated into Randox's RIQAS quality assessment program.
• Immunochemistry Diagnostic Reagents & Testing Solutions In vitro diagnostic reagents and testing solutions for immunochemistry applications, offered alongside clinical chemistry and hematology reagents as part of Randox's multi-assay diagnostic portfolio.
• Hematology Diagnostic Reagents & Testing Solutions In vitro diagnostic reagents and testing solutions for hematology testing, forming part of the integrated assay portfolio included in Randox's RIQAS external quality assessment program.
• Diagnostic Biochips Proprietary biochip technology acquired via the Cellix Limited acquisition, used in drug discovery and advanced diagnostic applications, supporting Randox's position in the biochips market.
• Veterinary Diagnostics Diagnostic testing services and reagents applied to veterinary use cases, integrated into Randox's RIQAS external quality-assurance program across multiple assay portfolios.
• Blood Biomarker Analysis Services Diagnostic testing services analyzing 110+ blood biomarkers across 11 body systems, delivered via partnership with preventive health platforms such as Lucis (serving 10,000+ members across France, UK, Ireland, and Portugal) to power AI-driven preventive health insights.

Named customers1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and flagship.

• Cormay DiagnosticscoreStrategic or Co-development Partner · 1 February 2025In February 2025, Poland-based Cormay Diagnostics S.A. partnered with Randox Laboratories Ltd. to integrate Cormay's assay portfolio into Randox's RIQAS external quality-assurance program, targeting hematology, clinical chemistry, and immunochemistry testing areas.
• LuciscoreTechnology or IntegrationLucis's AI platform analyzes over 110 blood biomarkers across 11 body systems through partnerships with Eurofins and Randox, serving over 10,000 members. Randox provides diagnostic testing infrastructure for Lucis's preventive health platform.
• MD One VenturesflagshipStrategic or Co-development PartnerMD One Ventures and Randox launched a security and biotech incubator called Randox for Builders, aimed at supporting early-stage companies that develop technologies for national resilience. The program offers access to Randox's diagnostics infrastructure, labs, and global market routes.
• Cormay DiagnosticscoreStrategic or Co-development PartnerCormay Diagnostics partnered with Randox International Quality Assessment Scheme to deliver external quality assessment services across hematology, clinical chemistry, and immunochemistry testing areas.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• QIAGEN: QIAGEN supplies molecular diagnostics reagents, sample-prep kits, and assay technologies used in clinical labs, comparable to Randox's IVD reagent and biochips (Cellix) capabilities in molecular and biomarker detection.
• DiaSorin: DiaSorin is a specialty IVD company focused on immunodiagnostics and molecular diagnostics reagents, closely mirroring Randox's specialty clinical chemistry and immunoassay reagent model.
• Bio-Rad Laboratories: Bio-Rad is a direct peer: it manufactures clinical chemistry, immunology, and quality-control reagents and runs its own external quality-assessment program (Unity), directly comparable to Randox's IVD reagents and RIQAS offering.
• Hologic: Hologic's diagnostics segment sells molecular and immunoassay IVD reagents and Panther systems to clinical labs, overlapping Randox's IVD reagent business and serving the same reference-lab and hospital customers.
• Eurofins Scientific: Eurofins runs a global clinical diagnostics lab network and is explicitly referenced as a partner feeding into Lucis's biomarker platform alongside Randox, making it a peer in clinical diagnostic testing services.

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is the global IVD incumbent with overlapping clinical chemistry, immunochemistry, and hematology menus and a broad hospital and reference-lab channel that competes head-to-head with Randox's core franchises.
• Siemens Healthineers: Siemens Healthineers offers Atellica and ADVIA Centaur systems for clinical chemistry and immunoassay plus a broad reagent menu, positioning it as a major incumbent competing with Randox in mid- and high-volume hospital labs.
• Danaher (Beckman Coulter Diagnostics): Beckman Coulter provides clinical chemistry, immunoassay, and hematology analyzers and reagents, directly overlapping Randox's core diagnostics portfolio and serving similar hospital and reference-lab customers.
• Abbott Diagnostics: Abbott's diagnostics division spans clinical chemistry, immunoassays, hematology, and point-of-care, competing with Randox across nearly the same menu and customer base of hospital and reference laboratories.

Emerging players

• Bio-Techne: Bio-Techne provides high-sensitivity immunoassay reagents, ELISA kits, and diagnostic biomarkers, intersecting Randox's clinical chemistry/immunochemistry reagent portfolio with focus on specialty and research-grade assays.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Customer concentration

• Xx.com/RandoxOfficial
• Facebookfacebook.com/RandoxOfficial

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Randox